A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Japanese Patients With Castration-resistant Prostate Cancer or Advanced Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2014
At a glance
- Drugs XOMA-213 (Primary)
- Indications Advanced breast cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis
- 10 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.